This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA  Topic Collections  • Cardiovascular System, Other  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Cardiovascular System  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: We agree with Dr Evans and colleagues that the uneven distribution of potential confounders is an important consideration in the interpretation of all trials. We have performed prespecified analyses exploring the potential role of glycemia or hypoglycemic drugs in our results. There were no significant differences between the aggressive and standard groups in the prevalence of metformin use (58% vs 53%, respectively; P = .29) and glitazone use (25% vs 24%, respectively; P = .65). The total percentages differ from Table 2 in the article because some patients were using both medications.

In addition, in multivariate models, changes in IMT or left ventricular mass index (LVMI) were not significantly related to any specific diabetes therapy, including lifestyle or use of sulfonylurea, metformin, or glitazone.¹ After adjustment for oral hypoglycemic use, the difference in carotid IMT remained 0.05 mm. Thus, we believe that the differences in IMT and LVMI that we . . . [Full Text of this Article]

Barbara V. Howard, PhD
barbara.v.howard@medstar.net
MedStar Research Institute
Hyattsville, Maryland

William James Howard, MD
Washington Hospital Center
Washington, DC

Robert E. Ratner, MD
MedStar Research Institute
Hyattsville

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Oral Hypoglycemic Use and the SANDS Trial
, , and
JAMA. ;300():389-389.
FULL TEXT